MGA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Magna International Inc (MGA) is not a strong buy for a beginner, long-term investor at this time. While the stock has some positive catalysts, such as bullish moving averages and a favorable regulatory environment for the auto industry, the lack of significant growth in financial performance, negative sentiment from Congress trading, and mixed analyst ratings suggest caution. The investor should wait for clearer signs of growth or a more favorable entry point.
The MACD is negative and expanding downward (-0.565), indicating bearish momentum. RSI is neutral at 33.505, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its key support level (S1: 60.73), with resistance at R1: 65.883. Overall, the technical indicators are mixed, with no strong buy signal.
Bullish moving averages indicate potential upward momentum.
Analysts from BofA and TD Securities have issued Buy ratings with price targets significantly above the current price.
The company is executing a buyback of 22M shares, which could support the stock price.
Congress trading data shows 4 sale transactions and no purchases, reflecting a cautious stance.
Financial performance in Q4 2025 was weak, with net income and EPS both dropping significantly.
Goldman Sachs issued a Sell rating, citing challenges in auto production, European exposure, and headwinds in key segments.
The MACD is bearish, and the stock is trading near support levels, indicating potential downside risk.
In Q4 2025, revenue increased by 2.07% YoY to $10.85B, but net income dropped to -$1M (-100.49% YoY), and EPS fell to 0 (-100% YoY). Gross margin improved to 12.21% (+12.74% YoY), but the overall financial performance was weak, with profitability metrics significantly declining.
Analyst ratings are mixed. BofA reinstated a Buy rating with an $80 price target, while TD Securities and CIBC also issued Buy/Outperform ratings with targets of $75 and $76, respectively. However, Goldman Sachs issued a Sell rating with a $49 target, citing significant challenges. Other firms, including Morgan Stanley and Barclays, maintained neutral ratings with modest price target increases.
